JAK3 INHIBITOR I
- CAS No.
- 202475-60-3
- Chemical Name:
- JAK3 INHIBITOR I
- Synonyms
- CS-2623;Janex 1;WHI-P131;WHI-P131, >98%;JANEX-1 ，S5903;JAK3 INHIBITOR I;JANEX-1;WHI-P131;WHI-P131(Janex 1);JANEX-1, 10 mM in DMSO;A JAK3 inhibitor WHI-P131
- CBNumber:
- CB7130537
- Molecular Formula:
- C16H15N3O3
- Molecular Weight:
- 297.31
- MDL Number:
- MFCD01862614
- MOL File:
- 202475-60-3.mol
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| JAK3 Inhibitor I - CAS 202475-60-3 - Calbiochem | 420101 | 5MG | $189 |
| WHI-P131 ≥98% | 10011246 | 1mg | $31 |
| WHI-P131 ≥98% | 10011246 | 5mg | $133 |
| WHI-P131 ≥98% | 10011246 | 10mg | $234 |
| WHI-P131 ≥98% | 10011246 | 25mg | $510 |
| More product size | |||
| Boiling point | 468.1±40.0 °C(Predicted) |
|---|---|
| Density | 1.336±0.06 g/cm3(Predicted) |
| storage temp. | Keep in dark place,Inert atmosphere,2-8°C |
| solubility | DMSO: 18 mg/mL, soluble |
| pka | 10.06±0.26(Predicted) |
| form | solid |
| color | yellow |
| Stability | Stable for 2 years from date of purchase as supplied. Protect from moisture. Solutions in DMSO may be stored at -20°C for up to 2 months. |
| InChI | InChI=1S/C16H15N3O3/c1-21-14-7-12-13(8-15(14)22-2)17-9-18-16(12)19-10-3-5-11(20)6-4-10/h3-9,20H,1-2H3,(H,17,18,19) |
| InChIKey | HOZUXBLMYUPGPZ-UHFFFAOYSA-N |
| SMILES | C1(O)=CC=C(NC2=C3C(=NC=N2)C=C(OC)C(OC)=C3)C=C1 |
| FDA UNII | 1J8Q49TR3I |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| WGK Germany | 3 |
| Storage Class | 11 - Combustible Solids |
JAK3 INHIBITOR I price More Price(40)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | 420101 | JAK3 Inhibitor I - CAS 202475-60-3 - Calbiochem | 202475-60-3 | 5MG | $189 | 2025-07-31 | Buy |
| Cayman Chemical | 10011246 | WHI-P131 ≥98% | 202475-60-3 | 1mg | $31 | 2024-03-01 | Buy |
| Cayman Chemical | 10011246 | WHI-P131 ≥98% | 202475-60-3 | 5mg | $133 | 2024-03-01 | Buy |
| Cayman Chemical | 10011246 | WHI-P131 ≥98% | 202475-60-3 | 10mg | $234 | 2024-03-01 | Buy |
| Cayman Chemical | 10011246 | WHI-P131 ≥98% | 202475-60-3 | 25mg | $510 | 2024-03-01 | Buy |
JAK3 INHIBITOR I Chemical Properties,Uses,Production
Description
WHI-P131 (202475-60-3) is a JAK3 inhibitor.Inhibits human glioblastoma cell adhesion and invasion.1 Increases survival in a mouse ALS model.2 Delays or prevents autoimmune type 1 diabetes in NOD mice.3 Exhibits potent anti-inflammatory activity in mouse models of peritonitis, colitis, cellulitis and systemic inflammatory response syndrome.4 Displays protective effects against myocardial ischemia and reperfusion injury in mouse models.5
Uses
Janex 1 is a Janus tyrosine kinase 3 (JAK3) inhibitor. Inhibition of JAK3 has been shown to exhibit protective action against the development of T1D in non-obese diabetic (NOD) mice. Janex 1 has been shown to suppresses proliferation of short-term cultured NOD CD4+ T cells through induction of apoptosis, while promoting survival of a particular population of long-term cultured cells. It ameliorates the expression of TNF-α-induced cell adhesion molecules and improves myocardial vascular permeability.
in vivo
JANEX-1 is administered at doses ranging from 5 to 100 mg/kg. Evaluation of CPK activity revealed a dose-response curve with an effective dose 50 (ED50) value of 7.44 mg/kg. Mice receiving JANEX-1 displayed significantly reduced CPK and LDH levels. In addition, the infarct size of JANEX-1-treated mice (30.16±2.79%) is significantly decreased when compared with I/R-operated mice (65.64±3.76%)[2]. JANEX-1 (WHI-P131) is absorbed rapidly, and the time to reach the maximum plasma JANEX-1 concentration (tmax) is 24.7±1.7 min. JANEX-1 is rapidly eliminated with an elimination half-life of 45.6±5.5 min. Although the predicted maximum plasma JANEX-1 concentration is 10.5 ± 0.8 μM, which is only half of the Cmax following i.v. administration of the same bolus dose, the i.p. bioavailability is 94.6% and the systemic exposure levels (i.e., AUC) are very similar to those observed after i.v. injection (17.1±2.2 μM h versus 18.1±1.2 μM h)[3].
IC 50
JAK3: 78 μM (IC50)
Background
WHI-P131 is a potent and selective inhibitor of Janus kinase 3 and glioblastoma cell adhesion and migration. This novel quinazoline derivative inhibits the enzymatic activity of constitutively active Jak3 without affecting Jak1, Jak2, or other family tyrosine kinases. WHI-P131 has also been shown to inhibit thrombin-induced tyrosine phosphorylation of Stat1 and Stat3. These properties make this compound useful when studying different diseases such as acute lymphoblastic leukemia, glioblastoma multiforme, and thromboembolism.
References
[1] R K NARLA. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4’-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3’-bromo-4’-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).[J]. Clinical Cancer Research, 1998, 4 10: 2463-2471.
[2] VUONG N. TRIEU . A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis[J]. Biochemical and biophysical research communications, 2000, 267 1: Pages 22-25. DOI:10.1006/bbrc.1999.1905
[3] MARINA CETKOVIC-CVRLJE . Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice[J]. Clinical immunology, 2003, 106 3: Pages 213-225. DOI:10.1016/s1521-6616(02)00049-9
[4] FATIH M. UCKUN . Anti-inflammatory activity profile of JANEX-1 in preclinical animal models[J]. Bioorganic & Medicinal Chemistry, 2008, 16 3: Pages 1287-1298. DOI:10.1016/j.bmc.2007.10.066
[5] YOUNG-BIN OH. Inhibition of Janus activated kinase-3 protects against myocardial ischemia and reperfusion injury in mice[J]. Experimental and Molecular Medicine, 2013, 45 5: e23-e23. DOI:10.1038/emm.2013.43
JAK3 INHIBITOR I Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 33024 | 60 |
| career henan chemical co | +86-0371-86658258 +8613203830695 | sales@coreychem.com | China | 29831 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19552 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32470 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
| Coresyn Pharmatech Co., Ltd. | +86-571-86626709 +86-18157142896 | cbc@coresyn.com | China | 9984 | 58 |
| ShenZhen Trendseen Biological Technology Co.,Ltd. | 13417589054 | trendseenbio@gmail.com | China | 11681 | 58 |
| SUZHOU SENFEIDA CHEMICAL CO.,LTD | +86-0512-83500002 +8618662433356 | 3899766280@qq.com | China | 26362 | 58 |
| Sichuan Biosynce Pharmatech Co., Ltd. | +8619950309693 | diane@biosynce.com | China | 4871 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 57505 | 58 |
View Lastest Price from JAK3 INHIBITOR I manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-02-25 | JANEX-1
202475-60-3
|
US $30.00-81.00 / mg | 99.81% | 10g | TargetMol Chemicals Inc. | ||
 |
2019-09-06 | 4-(4'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE
202475-60-3
|
US $1.00 / KG | 1KG | 98% | 20kg | Career Henan Chemical Co |
-
- JANEX-1
202475-60-3
- US $30.00-81.00 / mg
- 99.81%
- TargetMol Chemicals Inc.
-
- 4-(4'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE
202475-60-3
- US $1.00 / KG
- 98%
- Career Henan Chemical Co
202475-60-3(JAK3 INHIBITOR I)Related Search:
1of4
